This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J. Articles by Liu, J. M. Search for Related Content PubMed PubMed Citation Articles by Wang, J. Articles by Liu, J. M.

Inhibitors of Histone Deacetylase Relieve ETO-mediated Repression and Induce Differentiation of AML1-ETO Leukemia Cells

Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 [J. W., Y. S., J. M. L.], and Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 [R. L. R.]

The (8;21) translocation, found in 12% of acute myeloid leukemia (AML), creates the chimeric fusion product, AML1-ETO. Previously, we demonstrated that the ETO moiety recruits a transcription repression complex that includes the histone deacetylase (HDAC1) enzyme. Here, we used inhibitors of HDAC1 to study the pathophysiology of AML1-ETO. Both the potent inhibitor, trichostatin (TSA), and the well-known but less specific inhibitor, phenylbutyrate (PB), could partially reverse ETO-mediated transcriptional repression. PB was also able to induce partial differentiation of the AML1-ETO cell line, Kasumi-1. With the intention of developing a clinically useful protocol, we combined PB with a number of other agents that induced differentiation and apoptosis of Kasumi-1 cells. In summary, transcriptional repression mediated by AML1-ETO appears to play a mechanistic role in the t(8;21) AML, and relief of repression using agents such as PB (alone or in combination) may prove to be therapeutically useful.

This article has been cited by other articles:

				K. Schmidt, K. Seeger, C. Scheibenbogen, R. Bender, M. Abdulla, S. Sussmilch, A. Salama, and A. Moldenhauer Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia J. Leukoc. Biol., March 1, 2009; 85(3): 563 - 573. [Abstract] [Full Text] [PDF]

				O. M. Odenike, S. Alkan, D. Sher, J. E. Godwin, D. Huo, S. J. Brandt, M. Green, J. Xie, Y. Zhang, D. H. Vesole, et al. Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia Clin. Cancer Res., November 1, 2008; 14(21): 7095 - 7101. [Abstract] [Full Text] [PDF]

				R. Feng, H. Ma, C. A. Hassig, J. E. Payne, N. D. Smith, M. Y. Mapara, J. H. Hager, and S. Lentzsch KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling Mol. Cancer Ther., June 1, 2008; 7(6): 1494 - 1505. [Abstract] [Full Text] [PDF]

				J.-R. J. Yeh, K. M. Munson, Y. L. Chao, Q. P. Peterson, C. A. MacRae, and R. T. Peterson AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression Development, January 15, 2008; 135(2): 401 - 410. [Abstract] [Full Text] [PDF]

				S. Liu, R. B. Klisovic, T. Vukosavljevic, J. Yu, P. Paschka, L. Huynh, J. Pang, P. Neviani, Z. Liu, W. Blum, et al. Targeting AML1/ETO-Histone Deacetylase Repressor Complex: A Novel Mechanism for Valproic Acid-Mediated Gene Expression and Cellular Differentiation in AML1/ETO-Positive Acute Myeloid Leukemia Cells J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 953 - 960. [Abstract] [Full Text] [PDF]

				S. Frohling, R. F. Schlenk, S. Kayser, M. Morhardt, A. Benner, K. Dohner, H. Dohner, and for the German-Austrian AML Study Group Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Blood, November 15, 2006; 108(10): 3280 - 3288. [Abstract] [Full Text] [PDF]

				S. C. Dowdy, S. Jiang, X. C. Zhou, X. Hou, F. Jin, K. C. Podratz, and S.-W. Jiang Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2767 - 2776. [Abstract] [Full Text] [PDF]

				Y. Choi, K. E. Elagib, L. L. Delehanty, and A. N. Goldfarb Erythroid Inhibition by the Leukemic Fusion AML1-ETO Is Associated with Impaired Acetylation of the Major Erythroid Transcription Factor GATA-1. Cancer Res., March 15, 2006; 66(6): 2990 - 2996. [Abstract] [Full Text] [PDF]

				N. Gao, M. Rahmani, X. Shi, P. Dent, and S. Grant Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress Blood, January 1, 2006; 107(1): 241 - 249. [Abstract] [Full Text] [PDF]

				S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF]

				R. Kumar, A. E. Gururaj, R. K. Vadlamudi, and S. K. Rayala The Clinical Relevance of Steroid Hormone Receptor Corepressors Clin. Cancer Res., April 15, 2005; 11(8): 2822 - 2831. [Abstract] [Full Text] [PDF]

				A. Moldenhauer, R. C. Frank, J. Pinilla-Ibarz, G. Holland, P. Boccuni, D. A. Scheinberg, A. Salama, K. Seeger, M. A. S. Moore, and S. D. Nimer Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins J. Leukoc. Biol., September 1, 2004; 76(3): 623 - 633. [Abstract] [Full Text] [PDF]

				V. Ibanez, A. Sharma, S. Buonamici, A. Verma, S. Kalakonda, J. Wang, S. Kadkol, and Y. Saunthararajah AML1-ETO Decreases ETO-2 (MTG16) Interactions with Nuclear Receptor Corepressor, an Effect That Impairs Granulocyte Differentiation Cancer Res., July 1, 2004; 64(13): 4547 - 4554. [Abstract] [Full Text] [PDF]

				S. Takahashi, M. J. McConnell, H. Harigae, M. Kaku, T. Sasaki, A. M. Melnick, and J. D. Licht The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT Blood, June 15, 2004; 103(12): 4650 - 4658. [Abstract] [Full Text] [PDF]

				A. Castet, A. Boulahtouf, G. Versini, S. Bonnet, P. Augereau, F. Vignon, S. Khochbin, S. Jalaguier, and V. Cavailles Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition Nucleic Acids Res., April 1, 2004; 32(6): 1957 - 1966. [Abstract] [Full Text] [PDF]

				N. Chevallier, C. M. Corcoran, C. Lennon, E. Hyjek, A. Chadburn, V. J. Bardwell, J. D. Licht, and A. Melnick ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein Blood, February 15, 2004; 103(4): 1454 - 1463. [Abstract] [Full Text] [PDF]

				A. Gozzini, E. Rovida, P. Dello Sbarba, S. Galimbert, and V. Santini Butyrates, as a Single Drug, Induce Histone Acetylation and Granulocytic Maturation: Possible Selectivity on Core Binding Factor-Acute Myeloid Leukemia Blasts Cancer Res., December 15, 2003; 63(24): 8955 - 8961. [Abstract] [Full Text] [PDF]

				J. Krauter, K. Gorlich, O. Ottmann, M. Lubbert, H. Dohner, W. Heit, L. Kanz, A. Ganser, and G. Heil Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor Leukemias J. Clin. Oncol., December 1, 2003; 21(23): 4413 - 4422. [Abstract] [Full Text] [PDF]

				J.-W. Cheong, S. Y. Chong, J. Y. Kim, J. I. Eom, H. K. Jeung, H. Y. Maeng, S. T. Lee, and Y. H. Min Induction of Apoptosis by Apicidin, a Histone Deacetylase Inhibitor, via the Activation of Mitochondria-Dependent Caspase Cascades in Human Bcr-Abl-Positive Leukemia Cells Clin. Cancer Res., October 15, 2003; 9(13): 5018 - 5027. [Abstract] [Full Text] [PDF]

				L. Catley, E. Weisberg, Y.-T. Tai, P. Atadja, S. Remiszewski, T. Hideshima, N. Mitsiades, R. Shringarpure, R. LeBlanc, D. Chauhan, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood, October 1, 2003; 102(7): 2615 - 2622. [Abstract] [Full Text] [PDF]

				J. A. Plumb, P. W. Finn, R. J. Williams, M. J. Bandara, M. R. Romero, C. J. Watkins, N. B. La Thangue, and R. Brown Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 Mol. Cancer Ther., August 1, 2003; 2(8): 721 - 728. [Abstract] [Full Text] [PDF]

				J. L. Aron, M. R. Parthun, G. Marcucci, S. Kitada, A. P. Mone, M. E. Davis, T. Shen, T. Murphy, J. Wickham, C. Kanakry, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein Blood, July 15, 2003; 102(2): 652 - 658. [Abstract] [Full Text] [PDF]

				R. R. Rosato, J. A. Almenara, and S. Grant The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21CIP1/WAF1 1 Cancer Res., July 1, 2003; 63(13): 3637 - 3645. [Abstract] [Full Text] [PDF]

				C. Henderson, M. Mizzau, G. Paroni, R. Maestro, C. Schneider, and C. Brancolini Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA) J. Biol. Chem., March 28, 2003; 278(14): 12579 - 12589. [Abstract] [Full Text] [PDF]

				F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF]

				Z.-y. Wang Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis Hematology, January 1, 2003; 2003(1): 1 - 13. [Abstract] [Full Text] [PDF]

				S. Cote, A. Rosenauer, A. Bianchini, K. Seiter, J. Vandewiele, C. Nervi, and W. H. Miller Jr Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells Blood, September 18, 2002; 100(7): 2586 - 2596. [Abstract] [Full Text] [PDF]

				K. Jepsen and M. G. Rosenfeld Biological roles and mechanistic actions of co-repressor complexes J. Cell Sci., February 15, 2002; 115(4): 689 - 698. [Abstract] [Full Text] [PDF]

				S. A. Burel, N. Harakawa, L. Zhou, T. Pabst, D. G. Tenen, and D.-E. Zhang Dichotomy of AML1-ETO Functions: Growth Arrest versus Block of Differentiation Mol. Cell. Biol., August 15, 2001; 21(16): 5577 - 5590. [Abstract] [Full Text] [PDF]

				J. Zhang, B. A. Hug, E. Y. Huang, C. W. Chen, V. Gelmetti, M. Maccarana, S. Minucci, P. G. Pelicci, and M. A. Lazar Oligomerization of ETO Is Obligatory for Corepressor Interaction Mol. Cell. Biol., January 1, 2001; 21(1): 156 - 163. [Abstract] [Full Text]

				C. A Johnson Chromatin modification and disease J. Med. Genet., December 1, 2000; 37(12): 905 - 915. [Full Text]

				T. Maeda, M. Towatari, H. Kosugi, and H. Saito Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells Blood, December 1, 2000; 96(12): 3847 - 3856. [Abstract] [Full Text] [PDF]

				L. J. BURKE and A. BANIAHMAD Co-repressors 2000 FASEB J, October 1, 2000; 14(13): 1876 - 1888. [Abstract] [Full Text]

				T. E. Witzig, M. Timm, M. Stenson, P. A. Svingen, and S. H. Kaufmann Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents Clin. Cancer Res., February 1, 2000; 6(2): 681 - 692. [Abstract] [Full Text]

				S. Chakraborty, V. Senyuk, S. Sitailo, Y. Chi, and G. Nucifora Interaction of EVI1 with cAMP-responsive Element-binding Protein-binding Protein (CBP) and p300/CBP-associated Factor (P/CAF) Results in Reversible Acetylation of EVI1 and in Co-localization in Nuclear Speckles J. Biol. Chem., November 21, 2001; 276(48): 44936 - 44943. [Abstract] [Full Text] [PDF]

				H.-L. Kang, S. Benzer, and K.-T. Min Life extension in Drosophila by feeding a drug PNAS, January 22, 2002; 99(2): 838 - 843. [Abstract] [Full Text] [PDF]